Annals of internal medicine
-
Comment
In moderate-to-severe Crohn disease, upadacitinib increased clinical remission at 12 and 52 wk.
Loftus EV Jr, Panés J, Lacerda AP, et al. Upadacitinib induction and maintenance therapy for Crohn's disease. N Engl J Med. 2023;388:1966-1980. 37224198.